Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Amatangelo, Michael D., Quek, Lynn, Shih, Alan, Stein, Eytan M., Roshal, Mikhail, David, Muriel D., Marteyn, Benoit, Farnoud, Noushin Rahnamay, de Botton, Stephane, Bernard, Olivier A., Wu, Bin, Yen, Katharine E., Tallman, Martin S., Papaemmanuil, Elli, Penard-Lacronique, Virginie, Thakurta, Anjan, Vyas, Paresh, Levine, Ross L.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553578/
https://ncbi.nlm.nih.gov/pubmed/28588019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-779447
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars